1. Khan AA, Hanley DA, O’Brien CJ, Pasieka J, Ste-Marie LG, Rotstein LE, Rosen I, Young JEM, Josse RG, Bilezikian JP. Position paper: asymptomatic primary hyperparathyroidism – standards and guidelines for diagnosis and management in Canada. Endocr Pract. 2003;9(5): 400–5.
2. Rao DS, Agarwal G, Talpos GB, Phillips ER, Bandeira F, Mishra SK, Mithal A. Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J Bone Miner Res. 2002;17 Suppl 2:N75–80.
3. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2005;63(5):506–13.
4. Rao DS, Honasoge M, Divine GW, Phillips ER, Lee MW, Ansari MR, Talpos GB, Michael Parfitt A. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab. 2000;85:1054–8.
5. Clements MR, Davies M, Fraser DR, Lumb GA, Mawer EB, Adams PH. Metabolic inactivation of vitamin D is enhanced in primary hyperparathyroidism. Clin Sci (Lond). 1987; 73(6):659–64.